Kidney Cancer Pipeline Insights

• Kidney cancer also called renal carcinoma, is a type of disease that starts in the cells of the kidney, become malignant, and they grow out of control that forms a tumor.
• The most common types of kidney cancer of the renal pelvis are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC).
• These names will reflect the type of cell from which it is developed. These cancers develop in different ways, means that the diseases will be having different long-term outcomes, and are needed to be staged and treated in many ways. RCC accounts for about 80% of primary renal cancers, and TCC is responsible for most of the remainder. Usually, the kidney cancer drug is given to patients who reached the stage four renal cell carcinoma.
• The surgical removal of the affected cancerous cells will provide a complete cure of the disease from the kidney. So many drugs are also available, which will also help in the treatment of the disease if it is diagnosed at earlier disease stages.
• The various forms of cancer treatment methods that have been implemented among the currently approved drugs include immune modulation therapy, cytokine therapy, Vascular Endothelial Growth Factor (VEGF) inhibitor, and mTOR inhibitor.
• Increasing preference for the novel immunotherapies and immune-oncologic agents are pushing the use of targeted therapies to later lines of treatment or specific patient subpopulations.
• Several PD-1 and PD-L1 agents are found to be in early development and are being evaluated both as monotherapy and in combination with already approved immuno-oncology agents. The significant clinical profile of immuno-oncology drugs is represented in their rapid uptake and expansion of the indications.
• Biosimilar development is now gaining as a promising market opportunity in the kidney cancer therapeutics. So many biotech companies have already launched the Avastin biosimilars for several cancer indications in markets. Biological therapies are also used to shrink or control the advanced kidney cancer and helps people to live longer.
• Thus, biological therapies can be given for kidney cancer, which was already spread or is at high risk of coming back after the surgery.
• As the most of the kidney cancer indications are diagnosed at the end stage, the cancer seriousness and diagnosis play a significant role in the patients and physicians decided to go for paying the high price for treatment even for the marginal improvement in the outcome.
• Today, the U.S. Food and Drug Administration approved Sutent (sunitinib malate) for the treatment of adult patients as adjuvant who are at higher risk of kidney cancer (renal cell carcinoma) coming back even after a kidney got removed (nephrectomy).
• The primary branded drugs in the global kidney cancer drugs market like Nexavar (Sorafenib), Avastin (Bevacizumab), Inlyta (Axitinib), Votrient (Pazopanib), Sutent (Sunitinib), Torisel (Temsirolimus), Afinitor (Everolimus), and Proleukin (Interleukin-2/Aldesleukin). Sutent was found to be one of the highest demanded medicine in the past. Furthermore, drugs like Votrient are also expected to show the substantial demand over the forecast period. Now, most of the potential drugs are in phase 2 and phase 3 clinical trials.
• Less number of studies is found to be in phase 3 stage of clinical trial development. Medicines including Keytruda, Opdivo, AGS-003, Cabozantinib, and Dovitinib came to be commercialized in the market and launched in the coming years. Thus slow success rate in clinical trials for the cancer drugs and regulatory issues leads to the slowdown of the market.
• Factors including increased incidences of kidney cancers because of reduced activity and the sedentary lifestyle, growing of geriatric population, and the rise in cigarette smoking cases, government policies for providing better care for Kidney Cancer are the significant factors that drive the market.
• Further, higher prices of branded drugs and their side effects may hamper the growth of the market. Increase in the R&D investments, growing awareness program, the introduction of novel molecules for drug delivery, overexposure to radiation treatment for testicular cancer and increased mortality due to kidney cancer are going to boost the opportunities of the market in future.